Drugs interactions for

  • 2 Major drug interactions (including ingredients like Macimorelin, Rosiglitazone)
  • 356 Moderate drug interactions (including ingredients like Acarbose, Acebutolol, Acetazolamide)
  • 14 Minor drug interactions (including ingredients like Edetic acid, Esmolol, Fluoxymesterone)
372 interactions for
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and .
Macimorelin
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin human.
Rosiglitazone
The risk or severity of congestive heart failure can be increased when Insulin human is combined with Rosiglitazone.
Acarbose
The risk or severity of hypoglycemia can be increased when Acarbose is combined with Insulin human.
Acebutolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Acebutolol.
Acetazolamide
The risk or severity of hypoglycemia can be increased when Acetazolamide is combined with Insulin human.
Acetyl sulfisoxazole
The risk or severity of hypoglycemia can be increased when Acetyl sulfisoxazole is combined with Insulin human.
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin human.
Albuterol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Salbutamol.
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin human.
Alogliptin
The risk or severity of hypoglycemia can be increased when Alogliptin is combined with Insulin human.
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin human.
Amiloride
The therapeutic efficacy of Insulin human can be decreased when used in combination with Amiloride.
Aminosalicylic acid
The risk or severity of hypoglycemia can be increased when Aminosalicylic acid is combined with Insulin human.
Amiodarone
The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin human.
Amisulpride
The therapeutic efficacy of Insulin human can be decreased when used in combination with Amisulpride.
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Insulin human.
Amlodipine
The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin human.
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Insulin human.
Aripiprazole
The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole.
Aripiprazole lauroxil
The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole lauroxil.
Arsenic trioxide
The therapeutic efficacy of Insulin human can be decreased when used in combination with Arsenic trioxide.
Articaine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Articaine.
Asenapine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Asenapine.
Atazanavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Atazanavir.
Atenolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Atenolol.
Azilsartan medoxomil
The risk or severity of hypoglycemia can be increased when Azilsartan medoxomil is combined with Insulin human.
Baclofen
The therapeutic efficacy of Insulin human can be decreased when used in combination with Baclofen.
Balsalazide
The risk or severity of hypoglycemia can be increased when Balsalazide is combined with Insulin human.
Beclomethasone dipropionate
The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin human.
Benazepril
The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin human.
Bendroflumethiazide
The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin human.
Betamethasone
The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin human.
Betaxolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Betaxolol.
Bexagliflozin
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Bexagliflozin.
Bismuth subsalicylate
The risk or severity of hypoglycemia can be increased when Bismuth subsalicylate is combined with Insulin human.
Bisoprolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Bisoprolol.
Bosentan
The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin human.
Brexpiprazole
The therapeutic efficacy of Insulin human can be decreased when used in combination with Brexpiprazole.
Brinzolamide
The risk or severity of hypoglycemia can be increased when Brinzolamide is combined with Insulin human.
Bromocriptine
The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin human.
Bromotheophylline
The therapeutic efficacy of Insulin human can be decreased when used in combination with Bromotheophylline.
Budesonide
The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin human.
Bumetanide
The risk or severity of hypoglycemia can be increased when Bumetanide is combined with Insulin human.
Canagliflozin
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Canagliflozin.
Captopril
The risk or severity of hypoglycemia can be increased when Captopril is combined with Insulin human.
Cariprazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Cariprazine.
Carvedilol
The therapeutic efficacy of Insulin human can be increased when used in combination with Carvedilol.
Celecoxib
The risk or severity of hypoglycemia can be increased when Celecoxib is combined with Insulin human.
Ceritinib
The therapeutic efficacy of Insulin human can be decreased when used in combination with Ceritinib.
Chlorothiazide
The risk or severity of hypoglycemia can be increased when Chlorothiazide is combined with Insulin human.
Chlorpromazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorpromazine.
Chlorthalidone
The risk or severity of hypoglycemia can be increased when Chlorthalidone is combined with Insulin human.
Choline salicylate
The risk or severity of hypoglycemia can be increased when Choline salicylate is combined with Insulin human.
Ciclesonide
The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin human.
Ciprofloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Ciprofloxacin.
Citalopram
The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin human.
Clevidipine
The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin human.
Clobetasol propionate
The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin human.
Clocortolone
The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin human.
Clomipramine
Clomipramine may decrease the hypoglycemic activities of Insulin human.
Clonidine
The therapeutic efficacy of Insulin human can be increased when used in combination with Clonidine.
Clozapine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Clozapine.
Conivaptan
The therapeutic efficacy of Insulin human can be decreased when used in combination with Conivaptan.
Conjugated estrogens
The therapeutic efficacy of Insulin human can be decreased when used in combination with Conjugated estrogens.
Corticotropin
The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin human.
Cortisone acetate
The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin human.
Dabrafenib
The therapeutic efficacy of Insulin human can be decreased when used in combination with Dabrafenib.
Danazol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Danazol.
Dapagliflozin
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Dapagliflozin.
Darunavir
The risk or severity of hypoglycemia can be increased when Darunavir is combined with Insulin human.
Deflazacort
The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin human.
Delafloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Delafloxacin.
Desipramine
Desipramine may decrease the hypoglycemic activities of Insulin human.
Desogestrel
The therapeutic efficacy of Insulin human can be decreased when used in combination with Desogestrel.
Desonide
The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin human.
Desoximetasone
The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin human.
Desvenlafaxine
The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Insulin human.
Dexamethasone
The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin human.
Dexamethasone acetate
The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Insulin human.
Diazoxide
The risk or severity of hypoglycemia can be increased when Diazoxide is combined with Insulin human.
Diclofenamide
The risk or severity of hypoglycemia can be increased when Diclofenamide is combined with Insulin human.
Dienogest
The therapeutic efficacy of Insulin human can be decreased when used in combination with Dienogest.
Diflorasone
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin human.
Diflunisal
The risk or severity of hypoglycemia can be increased when Diflunisal is combined with Insulin human.
Difluprednate
The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin human.
Diltiazem
The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin human.
Disopyramide
The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin human.
Dorzolamide
The risk or severity of hypoglycemia can be increased when Dorzolamide is combined with Insulin human.
Doxepin
Doxepin may decrease the hypoglycemic activities of Insulin human.
Drospirenone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Drospirenone.
Dulaglutide
The risk or severity of hypoglycemia can be increased when Dulaglutide is combined with Insulin human.
Duloxetine
The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Insulin human.
Empagliflozin
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin human.
Enalapril
The risk or severity of hypoglycemia can be increased when Enalapril is combined with Insulin human.
Enalaprilat
The risk or severity of hypoglycemia can be increased when Enalaprilat is combined with Insulin human.
Epinephrine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Epinephrine.
Eplerenone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Eplerenone.
Eprosartan
The risk or severity of hypoglycemia can be increased when Eprosartan is combined with Insulin human.
Ertugliflozin
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ertugliflozin.
Escitalopram
The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin human.
Esterified estrogens
The therapeutic efficacy of Insulin human can be decreased when used in combination with Esterified estrogens.
Estetrol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Estetrol.
Estradiol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol.
Estradiol acetate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol acetate.
Estradiol cypionate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol cypionate.
Estradiol valerate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Estradiol valerate.
Estriol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Estriol.
Estrone sulfate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Estrone sulfate.
Etacrynic acid
The therapeutic efficacy of Insulin human can be decreased when used in combination with Etacrynic acid.
Ethanol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethanol.
Ethinylestradiol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethinylestradiol.
Ethosuximide
The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin human.
Ethynodiol diacetate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethynodiol diacetate.
Etonogestrel
The therapeutic efficacy of Insulin human can be decreased when used in combination with Etonogestrel.
Everolimus
The therapeutic efficacy of Insulin human can be decreased when used in combination with Everolimus.
Exenatide
The risk or severity of hypoglycemia can be increased when Exenatide is combined with Insulin human.
Fedratinib
The risk or severity of hypoglycemia can be increased when Fedratinib is combined with Insulin human.
Felodipine
The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin human.
Fenofibrate
The risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Insulin human.
Fenofibric acid
The risk or severity of hypoglycemia can be increased when Fenofibric acid is combined with Insulin human.
Finerenone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Finerenone.
Fluconazole
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Fluconazole.
Fludrocortisone
The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin human.
Flunisolide
The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin human.
Fluocinolone acetonide
The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin human.
Fluocinonide
The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin human.
Fluorometholone
The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin human.
Fluoxetine
The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Insulin human.
Fluphenazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Fluphenazine.
Flurandrenolide
The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin human.
Fluticasone furoate
The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin human.
Fluticasone propionate
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin human.
Fluvoxamine
The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Insulin human.
Follitropin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Follitropin.
Fosamprenavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Fosamprenavir.
Fosinopril
The risk or severity of hypoglycemia can be increased when Fosinopril is combined with Insulin human.
Furosemide
The risk or severity of hypoglycemia can be increased when Furosemide is combined with Insulin human.
Gatifloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Gatifloxacin.
Gemfibrozil
The risk or severity of hypoglycemia can be increased when Gemfibrozil is combined with Insulin human.
Gemifloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Gemifloxacin.
Gestodene
The therapeutic efficacy of Insulin human can be decreased when used in combination with Gestodene.
Glimepiride
The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Insulin human.
Glipizide
The risk or severity of hypoglycemia can be increased when Glipizide is combined with Insulin human.
Glucagon
The therapeutic efficacy of Insulin human can be decreased when used in combination with Glucagon.
Glyburide
The risk or severity of hypoglycemia can be increased when Glyburide is combined with Insulin human.
Goserelin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin.
Halcinonide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin human.
Haloperidol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol.
Histrelin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Histrelin.
Hydrochlorothiazide
The risk or severity of hypoglycemia can be increased when Hydrochlorothiazide is combined with Insulin human.
Hydrocortisone
The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin human.
Hydrocortisone acetate
The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin human.
Hydrocortisone butyrate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin human.
Hydrocortisone probutate
The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin human.
Hydrocortisone succinate
The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin human.
Hydrocortisone valerate
The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin human.
Hydroflumethiazide
The risk or severity of hypoglycemia can be increased when Hydroflumethiazide is combined with Insulin human.
Hydroxychloroquine
The therapeutic efficacy of Insulin human can be increased when used in combination with Hydroxychloroquine.
Hydroxyprogesterone caproate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydroxyprogesterone caproate.
Iloperidone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Iloperidone.
Imipramine
Imipramine may decrease the hypoglycemic activities of Insulin human.
Indapamide
The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin human.
Indinavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Indinavir.
Indomethacin
The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin human.
Insulin aspart
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin aspart.
Insulin degludec
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin degludec.
Insulin detemir
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin detemir.
Insulin glargine
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glargine.
Insulin glulisine
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glulisine.
Insulin lispro
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin lispro.
Isocarboxazid
The risk or severity of hypoglycemia can be increased when Isocarboxazid is combined with Insulin human.
Isoniazid
The therapeutic efficacy of Insulin human can be decreased when used in combination with Isoniazid.
Isosorbide
The therapeutic efficacy of Insulin human can be decreased when used in combination with Isosorbide.
Isradipine
The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin human.
Labetalol
The therapeutic efficacy of Insulin human can be increased when used in combination with Labetalol.
Lanreotide
The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Insulin human.
Leuprolide
The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide.
Levamlodipine
The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Insulin human.
Levofloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Levofloxacin.
Levomilnacipran
The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin human.
Levonorgestrel
The therapeutic efficacy of Insulin human can be decreased when used in combination with Levonorgestrel.
Linagliptin
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin human.
Linezolid
The risk or severity of hypoglycemia can be increased when Linezolid is combined with Insulin human.
Liothyronine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Liothyronine.
Lipoic acid
The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin human.
Liraglutide
Liraglutide may increase the hypoglycemic activities of Insulin human.
Lisinopril
The risk or severity of hypoglycemia can be increased when Lisinopril is combined with Insulin human.
Lithium citrate
The therapeutic efficacy of Insulin human can be increased when used in combination with Lithium citrate.
Lixisenatide
The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Insulin human.
Lomefloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Lomefloxacin.
Lonapegsomatropin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Lonapegsomatropin.
Lopinavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Lopinavir.
Losartan
The risk or severity of hypoglycemia can be increased when Losartan is combined with Insulin human.
Lumateperone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Lumateperone.
Lurasidone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Lurasidone.
Mafenide
The risk or severity of hypoglycemia can be increased when Mafenide is combined with Insulin human.
Magnesium sulfate
The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin human.
Mannitol
The therapeutic efficacy of Insulin human can be decreased when used in combination with Mannitol.
Mecasermin
The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Insulin human.
Medroxyprogesterone acetate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Medroxyprogesterone acetate.
Medrysone
The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin human.
Megestrol acetate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Megestrol acetate.
Mesalazine
The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin human.
Metformin
The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin.
Methazolamide
The risk or severity of hypoglycemia can be increased when Methazolamide is combined with Insulin human.
Methimazole
The therapeutic efficacy of Insulin human can be decreased when used in combination with Methimazole.
Methsuximide
The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin human.
Methyl salicylate
The risk or severity of hypoglycemia can be increased when Methyl salicylate is combined with Insulin human.
Methylene blue
The risk or severity of hypoglycemia can be increased when Methylene blue is combined with Insulin human.
Methylprednisolone
The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin human.
Methylprednisolone hemisuccinate
The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin human.
Metoclopramide
The therapeutic efficacy of Insulin human can be increased when used in combination with Metoclopramide.
Metolazone
The risk or severity of hypoglycemia can be increased when Metolazone is combined with Insulin human.
Metoprolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Metoprolol.
Metreleptin
Metreleptin may increase the hypoglycemic activities of Insulin human.
Mifepristone
The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Insulin human.
Miglitol
The risk or severity of hypoglycemia can be increased when Miglitol is combined with Insulin human.
Milnacipran
The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Insulin human.
Mitapivat
The risk or severity of hypoglycemia can be increased when Mitapivat is combined with Insulin human.
Moexipril
The risk or severity of hypoglycemia can be increased when Moexipril is combined with Insulin human.
Mometasone furoate
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin human.
Moxifloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin.
Nadolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Nadolol.
Nateglinide
The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Insulin human.
Nebivolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Nebivolol.
Nefazodone
The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Insulin human.
Nelfinavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Nelfinavir.
Niacin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Niacin.
Nicardipine
The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin human.
Nifedipine
The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Insulin human.
Nilotinib
The therapeutic efficacy of Insulin human can be decreased when used in combination with Nilotinib.
Nimodipine
The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin human.
Nisoldipine
The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin human.
Norethisterone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Norethisterone.
Norgestimate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Norgestimate.
Norgestrel
The therapeutic efficacy of Insulin human can be decreased when used in combination with Norgestrel.
Nortriptyline
Nortriptyline may decrease the hypoglycemic activities of Insulin human.
Octreotide
The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide.
Ofloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Ofloxacin.
Olanzapine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Olanzapine.
Olsalazine
The risk or severity of hypoglycemia can be increased when Olsalazine is combined with Insulin human.
Paliperidone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Paliperidone.
Palopegteriparatide
The therapeutic efficacy of Insulin human can be decreased when used in combination with Palopegteriparatide.
Parathyroid hormone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Parathyroid hormone.
Paroxetine
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin human.
Pasireotide
The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Insulin human.
Pegvisomant
The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.
Pentamidine
The risk or severity of hypoglycemia can be increased when Pentamidine is combined with Insulin human.
Pentoxifylline
The risk or severity of hypoglycemia can be increased when Pentoxifylline is combined with Insulin human.
Perindopril
The risk or severity of hypoglycemia can be increased when Perindopril is combined with Insulin human.
Perphenazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Perphenazine.
Phenelzine
The risk or severity of hypoglycemia can be increased when Phenelzine is combined with Insulin human.
Phentermine
The therapeutic efficacy of Insulin human can be increased when used in combination with Phentermine.
Phenytoin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Phenytoin.
Pinaverium
The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin human.
Pindolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Pindolol.
Pioglitazone
The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin human.
Polythiazide
The risk or severity of hypoglycemia can be increased when Polythiazide is combined with Insulin human.
Potassium
The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium.
Potassium cation
The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium cation.
Potassium citrate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium citrate.
Potassium Iodide
The therapeutic efficacy of Insulin human can be decreased when used in combination with Potassium Iodide.
Pramlintide
Pramlintide may increase the hypoglycemic activities of Insulin human.
Prednicarbate
The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin human.
Prednisolone
The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin human.
Prednisolone acetate
The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin human.
Prednisolone phosphate
The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin human.
Prednisone
The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin human.
Pregabalin
The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin human.
Probenecid
The risk or severity of hypoglycemia can be increased when Probenecid is combined with Insulin human.
Procaine
The risk or severity of hypoglycemia can be increased when Procaine is combined with Insulin human.
Procarbazine
The risk or severity of hypoglycemia can be increased when Procarbazine is combined with Insulin human.
Prochlorperazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Prochlorperazine.
Progesterone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Progesterone.
Promethazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Promethazine.
Propafenone
The therapeutic efficacy of Insulin human can be increased when used in combination with Propafenone.
Propranolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Propranolol.
Propylthiouracil
The therapeutic efficacy of Insulin human can be decreased when used in combination with Propylthiouracil.
Protirelin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Protirelin.
Protriptyline
Protriptyline may decrease the hypoglycemic activities of Insulin human.
Pseudoephedrine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Pseudoephedrine.
Quetiapine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Quetiapine.
Quinapril
The risk or severity of hypoglycemia can be increased when Quinapril is combined with Insulin human.
Quinine
The risk or severity of hypoglycemia can be increased when Quinine is combined with Insulin human.
Ramipril
The risk or severity of hypoglycemia can be increased when Ramipril is combined with Insulin human.
Rasagiline
The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin human.
Repaglinide
The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Insulin human.
Risperidone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Risperidone.
Ritonavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Ritonavir.
Ropinirole
The metabolism of Ropinirole can be increased when combined with Insulin human.
Rosuvastatin
The risk or severity of hypoglycemia can be increased when Rosuvastatin is combined with Insulin human.
Safinamide
The risk or severity of hypoglycemia can be increased when Safinamide is combined with Insulin human.
Salicylic acid
The risk or severity of hypoglycemia can be increased when Salicylic acid is combined with Insulin human.
Salmon calcitonin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Salmon calcitonin.
Saquinavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Saquinavir.
Saxagliptin
The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Insulin human.
Selegiline
The risk or severity of hypoglycemia can be increased when Selegiline is combined with Insulin human.
Semaglutide
The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Insulin human.
Sertraline
The risk or severity of hypoglycemia can be increased when Sertraline is combined with Insulin human.
Silver sulfadiazine
The risk or severity of hypoglycemia can be increased when Silver sulfadiazine is combined with Insulin human.
Sirolimus
The therapeutic efficacy of Insulin human can be decreased when used in combination with Sirolimus.
Sitagliptin
The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Insulin human.
Somapacitan
The therapeutic efficacy of Insulin human can be decreased when used in combination with Somapacitan.
Somatotropin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Somatotropin.
Somatrogon
The therapeutic efficacy of Insulin human can be decreased when used in combination with Somatrogon.
Sotagliflozin
The risk or severity of hypoglycemia can be increased when Sotagliflozin is combined with Insulin human.
Sotalol
The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin human.
Sparsentan
The risk or severity of hypoglycemia can be increased when Sparsentan is combined with Insulin human.
Spironolactone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Spironolactone.
Sulfacetamide
The risk or severity of hypoglycemia can be increased when Sulfacetamide is combined with Insulin human.
Sulfadiazine
The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Insulin human.
Sulfamethizole
The risk or severity of hypoglycemia can be increased when Sulfamethizole is combined with Insulin human.
Sulfamethoxazole
The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Insulin human.
Sulfasalazine
The risk or severity of hypoglycemia can be increased when Sulfasalazine is combined with Insulin human.
Sumatriptan
The risk or severity of hypoglycemia can be increased when Sumatriptan is combined with Insulin human.
Sunitinib
The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Insulin human.
Synthetic Conjugated Estrogens, A
The therapeutic efficacy of Insulin human can be decreased when used in combination with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, B
The therapeutic efficacy of Insulin human can be decreased when used in combination with Synthetic Conjugated Estrogens, B.
Tacrolimus
The therapeutic efficacy of Insulin human can be decreased when used in combination with Tacrolimus.
Tamsulosin
The risk or severity of hypoglycemia can be increased when Tamsulosin is combined with Insulin human.
Telmisartan
The risk or severity of hypoglycemia can be increased when Telmisartan is combined with Insulin human.
Temsirolimus
The therapeutic efficacy of Insulin human can be decreased when used in combination with Temsirolimus.
Teprotumumab
The therapeutic efficacy of Insulin human can be decreased when used in combination with Teprotumumab.
Terbutaline
The therapeutic efficacy of Insulin human can be decreased when used in combination with Terbutaline.
Teriparatide
The therapeutic efficacy of Insulin human can be decreased when used in combination with Teriparatide.
Testosterone undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Insulin human.
Thioridazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Thioridazine.
Thyroid, porcine
Thyroid, porcine may decrease the hypoglycemic activities of Insulin human.
Thyrotropin alfa
Thyrotropin alfa may decrease the hypoglycemic activities of Insulin human.
Timolol
The therapeutic efficacy of Insulin human can be increased when used in combination with Timolol.
Tipranavir
The therapeutic efficacy of Insulin human can be decreased when used in combination with Tipranavir.
Tirzepatide
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tirzepatide.
Tixocortol
The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin human.
Tolazamide
The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Insulin human.
Tolvaptan
The therapeutic efficacy of Insulin human can be decreased when used in combination with Tolvaptan.
Torasemide
The risk or severity of hypoglycemia can be increased when Torasemide is combined with Insulin human.
Trandolapril
The risk or severity of hypoglycemia can be increased when Trandolapril is combined with Insulin human.
Tranylcypromine
The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin human.
Triamcinolone
The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin human.
Triamterene
The therapeutic efficacy of Insulin human can be decreased when used in combination with Triamterene.
Trifluoperazine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Trifluoperazine.
Trimipramine
Trimipramine may decrease the hypoglycemic activities of Insulin human.
Triptorelin
The therapeutic efficacy of Insulin human can be decreased when used in combination with Triptorelin.
Trolamine salicylate
The risk or severity of hypoglycemia can be increased when Trolamine salicylate is combined with Insulin human.
Trovafloxacin
The therapeutic efficacy of Insulin human can be increased when used in combination with Trovafloxacin.
Ubidecarenone
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin human.
Ulobetasol
The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin human.
Valdecoxib
The risk or severity of hypoglycemia can be increased when Valdecoxib is combined with Insulin human.
Valsartan
The risk or severity of hypoglycemia can be increased when Valsartan is combined with Insulin human.
Vamorolone
The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Insulin human.
Vemurafenib
The risk or severity of hypoglycemia can be increased when Vemurafenib is combined with Insulin human.
Venlafaxine
The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Insulin human.
Verapamil
The risk or severity of hypoglycemia can be increased when Verapamil is combined with Insulin human.
Vorinostat
The therapeutic efficacy of Insulin human can be decreased when used in combination with Vorinostat.
Xylometazoline
The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin human.
Ziconotide
The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin human.
Ziprasidone
The therapeutic efficacy of Insulin human can be decreased when used in combination with Ziprasidone.
Zonisamide
The risk or severity of hypoglycemia can be increased when Zonisamide is combined with Insulin human.
Edetic acid
Edetic acid may increase the hypoglycemic activities of Insulin human.
Esmolol
Esmolol may increase the hypoglycemic activities of Insulin human.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Insulin human.
Landiolol
Landiolol may increase the hypoglycemic activities of Insulin human.
Levothyroxine
The therapeutic efficacy of Insulin human can be decreased when used in combination with Levothyroxine.
Lithium carbonate
The therapeutic efficacy of Insulin human can be decreased when used in combination with Lithium carbonate.
Methyltestosterone
Methyltestosterone may increase the hypoglycemic activities of Insulin human.
Nandrolone decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Insulin human.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Insulin human.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Insulin human.
Testosterone
Testosterone may increase the hypoglycemic activities of Insulin human.
Testosterone cypionate
Testosterone cypionate may increase the hypoglycemic activities of Insulin human.
Testosterone enanthate
Testosterone enanthate may increase the hypoglycemic activities of Insulin human.
Testosterone propionate
Testosterone propionate may increase the hypoglycemic activities of Insulin human.